Business ❯ Investing ❯ Pharmaceuticals

Manufacturing

Eli Lilly Active Pharmaceutical Ingredients Job Creation Johnson & Johnson AstraZeneca Biologics Supply Chain Biotechnology Vaccine Development Pharmaceutical Facilities Roche Novo Nordisk Genetic Medicine Cell Therapy U.S. Manufacturing Facilities Facility Development Eli Lilly and Company Roche Holdings AG

Eli Lilly Pours $4.5 Billion Into Indiana Plants, Opens Genetic-Medicine Site

The buildout strengthens U.S. supply for high‑demand obesity drugs plus diabetes treatments.

AbbVie to Build $1.4 Billion Injectable-Medicines Campus in Durham, N.C.

Novo Nordisk Invests €432 Million to Expand Athlone Plant for Oral GLP-1 Tablets

AbbVie to Invest $380 Million in Two North Chicago API Plants

Johnson & Johnson to Build $1 Billion Cell Therapy Plant in Pennsylvania

Eli Lilly Picks Lehigh Valley for $3.5 Billion Plant to Make Next-Gen Weight-Loss Drugs

Merck Breaks Ground on $3 Billion Virginia Plant in $70 Billion U.S. Expansion

AstraZeneca Breaks Ground on $4.5 Billion Virginia Plant With Expanded Cancer and Obesity Drug Production

Eli Lilly Chooses Houston for $6.5 Billion Plant to Produce APIs for Orforglipron and Other Drugs

J&J Commits $2 Billion to 10-Year Fujifilm Deal for North Carolina Biologics Hub

AbbVie to Build $195 Million API Facility in North Chicago

AstraZeneca Commits $50 Billion to U.S. Manufacturing and Research by 2030